London
· Delayed Price · Currency is GBP · Price in USD Aclaris Therapeutics Company Description
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States.
The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases.
The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Country | United States |
| Founded | 2012 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 89 |
| CEO | Neal Walker |
Contact Details
Address: 701 Lee Road Wayne, Delaware 19087 United States | |
| Phone | 484 324 7933 |
| Website | aclaristx.com |
Stock Details
| Ticker Symbol | 0H8T |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US00461U1051 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Neal Walker | Chief Executive Officer |
| Kevin Balthaser | Chief Financial Officer |
| Hugh M. Davis | Chief Operating Officer |